1. Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases.
- Author
-
Kumagai S, Nakajima T, and Muramatsu SI
- Subjects
- Humans, Animals, Parkinson Disease therapy, Parkinson Disease genetics, Nervous System Diseases genetics, Nervous System Diseases therapy, Gene Transfer Techniques, Aromatic-L-Amino-Acid Decarboxylases genetics, Aromatic-L-Amino-Acid Decarboxylases deficiency, Amino Acid Metabolism, Inborn Errors, Dependovirus genetics, Genetic Therapy methods, Genetic Vectors genetics
- Abstract
Introduction: In gene therapy with adeno-associated virus (AAV) vectors for diseases of the central nervous system, the vectors can be administered into blood vessels, cerebrospinal fluid space, or the brain parenchyma. When gene transfer to a large area of the brain is required, the first two methods are used, but for diseases in which local gene transfer is expected to be effective, vectors are administered directly into the brain parenchyma., Areas Covered: Strategies for intraparenchymal vector delivery in gene therapy for Parkinson's disease, aromatic l-amino acid decarboxylase (AADC) deficiency, and epilepsy are reviewed., Expert Opinion: Stereotactic intraparenchymal injection of AAV vectors allows precise gene delivery to the target site. Although more surgically invasive than intravascular or intrathecal administration, intraparenchymal vector delivery has the advantage of a lower vector dose, and preexisting neutralizing antibodies have little effect on the transduction efficacy. This approach improves motor function in AADC deficiency and led to regulatory approval of an AAV vector for the disease in the EU. Although further validation through clinical studies is needed, direct infusion of viral vectors into the brain parenchyma is expected to be a novel treatment for Parkinson's disease and drug-resistant epilepsy.
- Published
- 2024
- Full Text
- View/download PDF